Roche Tunisia & Libya Announces the Appointment of Matthieu Galais as General Manager
Roche Tunisia & Libya is pleased to announce the appointment of Matthieu Galais as the new General Manager of the pharmaceutical laboratory, succeeding Imene Ben Abdallah. This appointment aims to ensure continuity in the dynamic momentum established over the past few years. In his new role, Matthieu Galais will be responsible for pursuing the development of innovative health solutions, strengthening strategic partnerships, and continuing to support the evolution of healthcare systems in Tunisia and Libya for the benefit of patients.
With over 18 years of experience within the Roche group, in complex and rapidly changing environments, he brings a clear vision for the region to this new role. More than a function, it is a mission that he embarks on with conviction: to accelerate access to medical innovations where they are most needed, relying on local talent and solid partnerships.
Previous Experience
Prior to his appointment, Mr. Galais directed the Central Africa region, covering both Roche Pharma and Diagnostics activities in one of the most complex environments on the continent. He built an agile and learning organization capable of weaving solid partnerships with health actors, accompanying patients throughout their care journey, and maintaining constant dialogue with public and private authorities and stakeholders.
He notably contributed to integrating new oncology care models and strengthening diagnostic access programs, with a patient-centered and sustainable approach.
Leadership and Vision
Recognized for his inclusive and collaborative leadership, Mr. Galais places human wealth at the heart of collective performance. He is convinced that the strength of an organization lies in the diversity of its talents and in the ability to give them the means to act. His approach is based on listening, co-construction, and the ability to federate around a common vision, essential qualities for accompanying transformations in demanding environments.
His international and transversal career allows him to create solid links between local expertise and the global vision of the Roche pharmaceutical group.
Commitment to Healthcare in Tunisia and Libya
"Pursuing this journey in the service of health in Tunisia and Libya is for me much more than a new position, it's a commitment," confides Mr. Galais. "Innovation only makes sense if it truly transforms the lives of populations. Here, we have the chance to collaborate with partners who share this ambition — advancing together and co-constructing sustainable solutions to meet the health needs of the region."
Reinforcing Roche's Mission in Tunisia and Libya
This evolution is fully in line with the vision carried by the Africa region.
"Matthieu's taking office is part of the continuity of the work undertaken in Tunisia and Libya, where patient needs and healthcare system priorities are evolving to better meet population expectations," emphasizes Maturin Tchoumi, Africa Area Head – Roche Pharma International. "His international career, ability to federate, and commitment to access to innovation will make him an essential player in developing sustainable institutional partnerships and supporting the evolution of healthcare systems in both countries."
As health priorities evolve in Tunisia and Libya, this appointment reaffirms Roche's commitment to durably accompanying the two countries in strengthening their healthcare systems. Under Mr. Galais' direction, the subsidiary will continue to reinforce collaboration with local actors and contribute to a concrete impact for patients.
Roche's Global Commitment to Healthcare
This transition reflects Roche Tunisia & Libya's mission: to offer innovative health solutions while ensuring equitable access to care. It is also part of Roche's global commitment to transforming health on a global and local scale.
Present in Tunisia for over 30 years, Roche Tunisia is recognized today as a reference player in the health sector with a team of nearly 40 collaborators. The company operates in several key therapeutic areas, including oncology, neurology, rare diseases, hematology, and ophthalmology. Roche Tunisia works closely with health authorities, healthcare professionals, and Tunisian associations to address unmet medical needs, improve access to therapeutic innovations, and support clinical research. In this perspective, the company is committed to strengthening care pathways and contributing to the development of sustainable solutions for the Tunisian healthcare system.
As a long-term partner, Roche Tunisia works daily to improve the quality of life of patients in Tunisia and Libya, providing concrete and accessible health solutions.
About Roche
The parent company, founded in 1896 in Basel, Switzerland, is one of the world's leading manufacturers of branded medicines. Roche has become the world's largest biotechnology company and is also the global leader in in vitro diagnostics. Aiming for scientific excellence, Roche's ambition is to discover and develop medicines and diagnostics that improve the quality of life of patients and save lives worldwide. The company is at the forefront of personalized medicine and intends to strengthen its contribution by continuing to evolve patient care. To provide the best care for each individual, Roche cooperates with numerous partners and combines its expertise within the Diagnostics and Pharma divisions with data from clinical practice.
For over 125 years, sustainable development has been a fundamental pillar of Roche's activities. As a company focused on scientific innovation, our main contribution to society lies in the development of innovative medicines and diagnostic solutions that improve the quality of life. Roche is committed to achieving carbon neutrality by 2045 through initiatives such as Science Based Targets and Sustainable Markets.
